Last reviewed · How we verify
Orismilast modified release tablets
At a glance
| Generic name | Orismilast modified release tablets |
|---|---|
| Also known as | UNI50001, LEO32731 |
| Sponsor | UNION therapeutics |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS) (PHASE2)
- Study to Assess the Efficacy and Safety of Orismilast in Psoriasis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Orismilast modified release tablets CI brief — competitive landscape report
- Orismilast modified release tablets updates RSS · CI watch RSS
- UNION therapeutics portfolio CI